Jason P Rhodes sold $1.9M of DYN
director at Dyne Therapeutics, Inc.. 106,723 shares at an average of $18.14, traded May 4, 2026, filed May 6, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.9M at market
- 0Share of holdings soldSold 6.8% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.6%, 3m +38.9%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001577014-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 4, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,136 | $18.00 | $56k | 1,574,270 | May 6, 2026 |
| May 4, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,241 | $18.00 | $112k | 4,933,196 | May 6, 2026 |
| May 4, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -61 | $18.00 | $1,098 | 8,450 | May 6, 2026 |
| May 4, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,466 | $18.00 | $44k | 1,156,457 | May 6, 2026 |
| May 5, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -3,056 | $18.03 | $55k | 1,571,214 | May 6, 2026 |
| May 5, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -6,081 | $18.03 | $110k | 4,927,115 | May 6, 2026 |
| May 5, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -60 | $18.03 | $1,082 | 8,390 | May 6, 2026 |
| May 5, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -2,403 | $18.03 | $43k | 1,154,054 | May 6, 2026 |
| May 6, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -21,926 | $18.18 | $399k | 1,549,288 | May 6, 2026 |
| May 6, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -43,621 | $18.18 | $793k | 4,883,494 | May 6, 2026 |
| May 6, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -428 | $18.18 | $7,781 | 7,962 | May 6, 2026 |
| May 6, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -17,244 | $18.18 | $313k | 1,136,810 | May 6, 2026 |
Related signals
Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $40k 2,500 shares | +10% | |
| 30Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $107k 5,658 shares | -2% | |
| 20Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $116k 5,035 shares | -3% | |
| 15Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $25k 1,085 shares | -1% | |
| 31Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $131k 4,986 shares | -1% | |
| 55Moderate | Dyne Therapeutics, Inc. | Jason P Rhodes director | $65M 2,586,928 shares | -64% | |
| 23Weak | Dyne Therapeutics, Inc. | Erick Lucera Chief Financial Officer | $47k 1,797 shares | -1% | |
| 16Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $41k 1,556 shares | -1% | |
| 10Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $5,939 226 shares | -0% | |
| 20Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $6.7M 261,460 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.